#imagingdata

The Future of AI in Medical Devices: FDA Guidelines & the Value of Imaging Data Artificial Intelligence (AI) and Machine Learning (ML) are transforming medical devices — enabling faster, more accurate diagnostics, smarter treatment plans, and adaptive learning from real-world use. But as AI evolves, so does the regulatory landscape. In our latest blog, the Segmed Team explores: 🔹 How the FDA’s evolving guidance supports AI/ML-based medical devices 🔹 Key challenges for AI developers, from dataset bias to privacy hurdles 🔹 The critical role of real-world imaging data (RWiD) in creating regulatory-grade, generalizable AI models With access to 100M de-identified, annotated imaging studies from 2,000+ healthcare locations worldwide, Segmed empowers AI and MedTech developers to build safer, effective, and FDA-ready medical devices. 📖 Read the full blog: https://www.segmed.ai/resources/blog/future-of-ai-powered-medical-devices-fda-insights

Essential Real-World Data for Alzheimer’s breakthroughs The value of real-world imaging data in Alzheimer’s research is rapidly gaining recognition. From enabling the discovery and validation of biomarkers, tracking disease progression, and supporting clinical trial optimization, to providing insights for personalized medicine, these datasets are essential for improving patient care and drug development. By integrating advanced AI and machine learning techniques, we can further unlock the potential of imaging data, making diagnosis and drug development more efficient. Segmed provides regulatory-grade, tokenized imaging datasets that help life sciences companies by helping understand disease to develop precise and effective treatments.

Segmed’s tokenized, longitudinal datasets are uniquely positioned to support Alzheimer’s research with data that reflects real-world patient journeys. These multimodal datasets allow Pharma companies to gain a 360-degree view of Alzheimer’s progression, aiding in both R&D and Real-World Evidence (RWE) generation. Connect with us to explore how our datasets can support your mission to create better therapies for Alzheimer’s patients.